Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | S1PR4 | O95977 | 11/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790468 | 0.84 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL10562972 | 0.81 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL7011056 | 0.81 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL2986307 | 0.80 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL31358001 | 0.80 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL23421449 | 0.79 | MAPT (0.47) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL4763882 | 0.77 | ALDH1A1 (0.43) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL3900697 | 0.76 | PDGFRA (0.53) | NPC1RAB9ASMN1; SMN2S1PR4 | |
| SCHEMBL799663 | 0.76 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2S1PR4MAPT | |
| SCHEMBL10779236 | 0.76 | ALDH1A1 (0.58) | NPC1RAB9ASMN1; SMN2S1PR4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689652-B | Fused heterocyclic derivative, preparation method and medical application thereof | 北京诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-2582675-B1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | CHANGZHOU LE SUN PHARMACEUTICALS LTD (CN) | 2016-06-08 | — | — | EP | disclosed |
| EP-2582675-B1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | CHANGZHOU LE SUN PHARMACEUTICALS LTD (CN) | 2016-06-08 | — | — | EP | disclosed |
| US-9346822-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9346822-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2003007945-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-01-30 | — | — | WO | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2002012199-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
| EP-1069112-A1 | N-(PHENYLSULFONYL) PICOLINAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND HERBICIDE | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-4812454-A | Nitromethylene derivatives and their use as insecticides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-03-14 | — | — | US | disclosed |
| US-4772620-A | MITICIDES, PARASITICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1988-09-20 | — | — | US | disclosed |
| EP-0212600-A2 | Nitromethylene derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | IDO1, IDO2, INMT | NPC1 3013/4885RAB9A 2349/4885SMN1; SMN2 3030/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | NPC1 53/4885RAB9A 3576/4885SMN1; SMN2 4386/4885 |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | IDO1, IDO2, INMT | NPC1 3013/4885RAB9A 2349/4885SMN1; SMN2 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.